New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
08:44 EDTTINYHarris & Harris signs several agreements with Patia Biopharma
Harris & Harris notes the announcement by its portfolio company, Metabolon that it has signed several exclusive multi-year, royalty-based research collaboration and licensing agreements with Patia Biopharma. The research collaboration provides Metabolon's Quantose IR technology for use in several diabetes prevention studies in Mexico. The license agreement provides exclusive access in Mexico to Metabolon's prediabetes test technology for assessing insulin resistance in the general population of Mexico through Patia and Clinica Ruiz's network of laboratories. Under the terms of the agreements, Patia and its affiliates will use Metabolon's Quantose IR technology in unprecedented large-scale studies in Mexico to test for prediabetes in up to 3M overweight or obese adults and secondary school students who are obese and/or have a family history of diabetes. The goal of these studies is to detect prediabetes early and prescribe treatment to prevent progression to Type 2 diabetes. Testing will be carried out over four years, beginning with pilot studies in FY14.
News For TINY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 3, 2016
09:32 EDTTINYHarris & Harris, Mersana Therapeutics, expand partnership with Technip
Harris & Harris notes the announcement by its portfolio company, Mersana Therapeutics, that Mersana and Takeda Pharmaceutical have entered a new strategic partnership granting Takeda rights to Mersana's lead product candidate, XMT-1522, outside the United States and Canada. The deal also expands an existing collaboration between the companies to provide Takeda with additional access to Mersana's Fleximer antibody-drug conjugate, or ADC, platform and grants Mersana an option at the end of Phase 1 to co-develop and co-commercialize one of these programs in the United States. In addition, the companies will co-develop new payloads for use with ADCs. XMT-1522 is an investigational, Fleximer-based ADC therapy that targets HER2-expressing tumors, including breast, gastric and non-small cell lung cancers. Mersana will receive an upfront payment of $40M and an additional payment of $20M upon clearance of the IND for XMT-1522 by the FDA. Subject to the success of the XMT-1522 and ADC programs, Mersana is eligible to receive milestone payments of more than $750 million combined, as well as royalties. Takeda will also invest up to $20M in equity in future rounds of Mersana financing.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use